Inclusion Criteria:
* Adults aged 19 to 65 years, inclusive, as of the date of written informed consent.
* Subjects who have a glabellar line severity score of 2 (moderate) or greater, as assessed by the investigator, when maximizing frown (frowning) at the screening and randomization visits.
* Subjects who are able to comply with the visit schedule according to the clinical trial procedures.
* Subjects who signed voluntarily in informed consent form and fully understood about this clinical trial.
Exclusion Criteria:
* Subjects with a known history of allergy or hypersensitivity to the investigational product or any of its components (or ingredients).
* Subjects with a systemic neuromuscular junction disorder that may affect neuromuscular function. (myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis etc.)
* Subjects with an infection or skin disease at the treatment injection sites.
* Subjects with structural or physical facial features (or conditions) that may hinder or prevent improvement (facial nerve palsy or eyebrow/eyelid ptosis, marked facial asymmetry etc.)
* Subjects who have received drugs with systemic muscle relaxant action within 4 weeks of screening
* Subjects who have received botulinum toxin products within 24 weeks prior to screening, or who are expected to receive botulinum toxin treatment during the study.
* Subjects who have received an investigational product or medical device in another clinical trial within 4 weeks prior to screening, or who are planning to participate in another clinical trial (excluding non-interventional observational studies).
* Subjects with a history of, or planned, surgery or procedures in the glabellar or forehead region that may affect the efficacy evaluation during the following period
1. Collagen dermal fillers within 16 weeks prior to screening
2. Permanent soft tissue augmentation, face Lifting, implant, or fat grafting within 24 weeks prior to screening
3. Hyaluronic acid dermal fillers, dermal resurfacing, chemical or mechanical peeling, skin peeling, or dermal photorejuvenation within 52 weeks prior to screening
4. Dermal fillers other than hyaluronic acid or collagen, or nonpermanent soft tissue fillers within 104 weeks prior to screening
5. Subjects who are planning to undergo facial aesthetic procedures or surgeries (such as dermal fillers, dermal photorejuvenation, chemical or mechanical peeling, facial plastic surgery, etc.) during the study
* Subjects who have received retinoid products (such as isotretinoin, alitretinoin, etc.) during the following period
1. Oral or other systemic formulations within 24 weeks prior to screening
2. Topical formulations applied to the face within 12 weeks prior to screening
* Pregnant and lactating women
* Subjects who are planning to become pregnant during the study, or who do not agree to use medically acceptable methods of contraception.
* Subjects with any comorbid conditions or diseases that, in the opinion of the investigator, would interfere with study participation (such as malignant tumors or immunodeficiency)
* Subjects who have received anticoagulants, antiplatelets, or systemic non-steroidal anti-inflammatory drugs (NSAIDs) within 1 week prior to administration of the investigational product (low-dose aspirin of 325 mg/day or less administered for antithrombotic purposes is permitted).
* Subjects who has physically untreatable glabellar lines like that can't be spread out even if someone forces it to spread out
* Subjects who are not eligible for this study based on investigator's judgement.
